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Aspartame (APM) is one of the most widely
used artificial sweeteners in the world. First
approved by the U.S. Food and Drug
Administration (FDA) for limited use in solid
food in 1981, its authorization was extended
to soft drinks in 1983 and then approved as a
general sweetener in 1996 (FDA 1981, 1983,
1996). Likewise, the sweetener was approved
for general use in the European Union in
1994 (EC Directive 1994). APM is now pre-
sent in > 6,000 consumer packaged goods
and in nearly 500 pharmaceutical products,
including children’s medicines (Aspartame
Information Center 2005). In the United
States, > 70% of aspartame sales are attrib-
uted to soft drinks (American Dietetic
Association 2004). The acceptable daily
intake (ADI) of aspartame is currently
50 mg/kg body weight (bw) in the United
States and 40 mg/kg bw in the European
Union for both children and adults. Daily
consumption of artificial sweeteners by
women of childbearing age and by children
has been estimated at 2.5–5.0 mg/kg bw
(Butchko et al. 2002). In a study of Swedish
diabetics, the general APM intake was lower
than the ADI, but the worst-case calculation
of intake in the children’s group was 114% of
the ADI (Ilbäck et al. 2003).
APM is metabolized in the gastric tract of
rodents, nonhuman primates, and humans to
its three constituents: aspartic acid, phenyl-
alanine, and methanol. When absorbed,
aspartic acid is transformed into alanine plus
oxaloacetate (Stegink 1984); phenylalanine is
transformed mainly into tyrosine and, to a
lesser extent, phenylethylamine and phenyl-
pyruvate (Harper 1984); and methanol is
transformed into formaldehyde and then to
formic acid (Opperman 1984).
In vitro and in vivo tests demonstrate that
APM is not genotoxic. Likewise, long-term
carcinogenicity studies conducted by the
manufacturers of aspartame using rats and
mice in the 1970s and 1980s did not demon-
strate any carcinogenic effects. A detailed
review of the genotoxicity and carcinogenicity
studies available to date on APM has been
published previously (Belpoggi et al. 2006;
Soffritti et al. 2005, 2006). In our opinion,
the small number of animals used per sex and
per group and the termination of these
experiments after 110 weeks of age, rather
than observing animals over their life span,
represent limiting factors when evaluating the
carcinogenic risk or safety of artiﬁcial sweet-
eners such as aspartame. It was for this rea-
son, together with the growing use of APM in
industrialized countries, that we designed and
performed a mega-experiment using seven
groups of Sprague-Dawley rats (100–150 per
sex per group) treated with APM in feed at
various dose levels (including one very close
to the ADI for humans), from 8 weeks of age
until natural death (Belpoggi et al. 2006;
Soffritti et al. 2005, 2006). The study
demonstrated for the ﬁrst time that APM is a
multipotential carcinogenic agent, capable of
inducing, in our experimental conditions a)a
signiﬁcant, dose-related increased incidence of
malignant tumor–bearing animals in males
(p ≤ 0.05) and in females (p ≤ 0.01), particu-
larly in females treated at 50,000 ppm
(p ≤ 0.01); b) a significant dose-related
increase in lymphomas/leukemias in both
males (p ≤ 0.05) and females (p ≤ 0.01), par-
ticularly in females treated at doses of 100,000
(p ≤ 0.01), 50,000 (p ≤ 0.01), 10,000
(p ≤ 0.05), 2,000 (p ≤ 0.05), or 400 ppm
(p ≤ 0.01); c) a significant, dose-related
increased incidence (p ≤ 0.01) of transitional
cell carcinomas of the renal pelvis and ureter
and their precursors (dysplasias) in females
treated at 100,000 (p ≤ 0.01), 50,000
(p ≤ 0.01), 10,000 (p ≤ 0.01), 2,000
(p ≤ 0.05), or 400 ppm (p ≤ 0.05); d) a
signiﬁcant, dose-related increased incidence of
malignant schwannomas of peripheral nerves
(p ≤ 0.05) in males (Belpoggi et al. 2006;
Soffritti et al. 2005, 2006).
Given the consolidated experience of the
European Ramazzini Foundation (ERF) in
the conduct of long-term bioassays and the
large number of rodents used in the study, the
results attracted the attention of the scientiﬁc
community, consumer and industry associa-
tions, and the national and international agen-
cies responsible for food safety, including the
Italian Superior Council of Health, the
European Food Safety Authority (EFSA), the
U.S. FDA, Health Canada, and others. At
their request, we provided each of these agen-
cies with all available raw data related to
the study.
To our knowledge, only the EFSA has
issued an ofﬁcial opinion on our study, releas-
ing on 5 May 2006 a 40-page report in which
they concluded that it is not necessary to
revise their previous opinion on the absolute
safety of APM (EFSA 2006).
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Life-Span Exposure to Low Doses of Aspartame Beginning during Prenatal
Life Increases Cancer Effects in Rats
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BACKGROUND: In a previous study conducted at the Cesare Maltoni Cancer Research Center of the
European Ramazzini Foundation (CMCRC/ERF), we demonstrated for the ﬁrst time that aspartame
(APM) is a multipotent carcinogenic agent when various doses are administered with feed to
Sprague-Dawley rats from 8 weeks of age throughout the life span.
OBJECTIVE: The aim of this second study is to better quantify the carcinogenic risk of APM, begin-
ning treatment during fetal life. 
METHODS: We studied groups of 70–95 male and female Sprague-Dawley rats administered APM
(2,000, 400, or 0 ppm) with feed from the 12th day of fetal life until natural death.
RESULTS: Our results show a) a signiﬁcant dose-related increase of malignant tumor–bearing ani-
mals in males (p < 0.01), particularly in the group treated with 2,000 ppm APM (p < 0.01); b) a
significant increase in incidence of lymphomas/leukemias in males treated with 2,000 ppm
(p < 0.05) and a signiﬁcant dose-related increase in incidence of lymphomas/leukemias in females
(p < 0.01), particularly in the 2,000-ppm group (p < 0.01); and c) a signiﬁcant dose-related increase
in incidence of mammary cancer in females (p < 0.05), particularly in the 2,000-ppm group
(p < 0.05). 
CONCLUSIONS: The results of this carcinogenicity bioassay conﬁrm and reinforce the ﬁrst experi-
mental demonstration of APM’s multipotential carcinogenicity at a dose level close to the accept-
able daily intake for humans. Furthermore, the study demonstrates that when life-span exposure to
APM begins during fetal life, its carcinogenic effects are increased. 
KEY WORDS: artificial sweeteners, aspartame, carcinogenicity, lymphomas/leukemias, mammary
cancers, prenatal exposure, Sprague-Dawley. Environ Health Perspect 115:1293–1297 (2007).
doi:10.1289/ehp.10271 available via http://dx.doi.org/ [Online 13 June 2007]Subsequent to our findings of hemato-
poietic cancers in rats, and in light of persis-
tent concerns among the scientiﬁc community
of an association between APM and brain can-
cers, Lim et al. (2006) published the results of
a study that assessed the correlation between
the consumption of aspartame-containing
beverages and the incidence of these types of
cancers. The findings were based on data
derived from a prospective study conducted by
the U.S. National Institutes of Health and the
American Association of Retired Persons,
using a cohort of > 285,000 men and
> 188,000 women between 50 and 71 years of
age, who had satisfactorily responded to a self-
administered food frequency questionnaire.
The questionnaire included questions on the
consumption of beverages (soft drinks, fruit
drinks, sweetened iced tea) potentially con-
taining APM during the previous year. The
questionnaires were mailed from 1995 to
1996 and the follow-up lasted until 2000. The
conclusions of the study (Lim et al. 2006) did
not support the hypothesis that APM increases
hematopoietic or brain cancer risks. 
Recently a group of Italian authors
(Gallus et al. 2007) published the results of an
integrated network of case–control studies
conducted in Italy between 1991 and 2004
on the potential correlation between artiﬁcial
sweeteners (including APM) and cancer. The
authors interviewed patients with histologi-
cally conﬁrmed cancers of the oral cavity and
pharynx (598), esophagus (304), colon
(1,225), rectum (728), larynx (460), breast
(2,569), ovary (1,031), prostate (1,294), and
kidney (renal cell carcinoma 767). Controls
were 7,028 patients (3,301 men and 3,727
women) admitted to the same hospitals for
acute, nonneoplastic disorders. Cases and
controls were interviewed during their hospi-
tal stay, using a questionnaire on subjects’
usual diet in the 2 years before diagnosis. The
results reported a lack of association between
artiﬁcial sweeteners and the risk of the afore-
mentioned cancers. 
As soon as we perceived the carcinogenic
effects of APM during the elaboration of the
data in our first mega-experiment (Belpoggi
et al. 2006; Soffritti et al. 2005, 2006), we
planned an integrated program of long-term
bioassays, beginning treatment from prenatal
life, on > 4,000 rats and mice in order to better
quantify the carcinogenic risks of aspartame. In
this report we present the results of a second
study on APM in which male and female
Sprague-Dawley rats were exposed to very low
doses of APM in feed (100 or 20 mg/kg bw)
from fetal life until natural death. 
Materials and Methods
The APM used in this study was produced by
Ajinomoto (Gravelines, France) and supplied
by Giusto Faravelli S.p.A. (Milan, Italy). The
purity of the APM, as determined by an
infrared absorption spectrophotometer assay,
was > 98.7%: diketopiperazine was < 0.3%
and L-phenylalanine was < 0.5%. APM was
added to the standard diet, which has been
used for > 30 years at the Cesare Maltoni
Cancer Research Center (CMCRC)/ERF, at
APM concentrations of 2,000, 400, or 0 ppm
to simulate an assumed daily APM intake of
100, 20, or 0 mg/kg bw. The feed was supplied
by the producer on a monthly basis. The sta-
bility of the aspartame in feed was analyzed
before the start of the study and periodically
conﬁrmed throughout the course of the bio-
phase. The daily APM consumption (mil-
ligrams per kilogram body weight) was
calculated estimating the average body weight
for both males and females as 400 g for the
duration of the experiment and the daily con-
sumption of feed as 20 g/day.
The feed was supplied ad libitum to groups
of 70–95 male and female Sprague-Dawley rats
from the colony of the CMCRC/ERF. The
basic tumorigram of this strain of rats is well
known. Treatment began during fetal life, with
administration of APM in feed to female
breeders from the 12th day of pregnancy,
when organogenesis is completed and before
which time many tissues and organs are refrac-
tory to the effects of carcinogenic agents
[International Agency for Research on Cancer
(IARC) 1973]. The breeders were sacrificed
after weaning, and treatment of the offspring
lasted until natural death. Control animals
received the same feed without APM.
At 4–5 weeks of age (after weaning), the
experimental animals were identified by ear
punch, separated by sex, and assigned to a
respective dose group, depending on the APM
concentration administered to the breeder.
They were then housed ﬁve per cage in poly-
carbonate cages (41 × 25 × 15 cm) with stain-
less-steel wire tops and a shallow layer of white
wood shavings as bedding, and kept in a room
Soffritti et al.
1294 VOLUME 115 | NUMBER 9 | September 2007 • Environmental Health Perspectives
Figure 1. Effects of APM exposure on feed consumption, body weight, and survival. Mean daily feed consumption in males (A) and females (B). (C) Mean body
weights in males (M) and females (F). Survival in males (D) and females (E). Arrows indicate the start of the experiment.
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2,000 ppmused only for this experiment. The room was
maintained at a temperature of 23 ± 2°C and
relative humidity of 50–60%.
All animals were kept under observation
until natural death. The experiment was con-
ducted according to Italian law regulating the
use and humane treatment of animals for scien-
tific purposes (Decreto Legislativo N. 116
1992).
Mean daily drinking water and feed con-
sumption were measured per cage, and body
weight was measured individually, beginning
at 6 weeks of age and continuing once each
week for the ﬁrst 13 weeks, then every 2 weeks
until animals reached 110 weeks of age.
Measurement of body weight continued every
2 weeks until the end of the experiment. To
detect and register all gross lesions, the animals
were clinically examined every 2 weeks for the
duration of the experiment. To evaluate the
status and behavior of the animals and to limit
the postmortem modifications, a patrol was
performed three times daily Monday–Friday
and twice on Saturdays, Sundays, and holidays.
Deceased animals were registered and kept
refrigerated for a maximum of 16–19 hr at 4°C
until necropsy. 
The biophase ended at 147 weeks with the
death of the last animal at the age of
144 weeks. Upon death, all animals underwent
complete necropsy. Histopathology was rou-
tinely performed on the following organs and
tissues of each animal from each group: skin
and subcutaneous tissue, mammary gland, the
brain (three sagittal sections), pituitary gland,
Zymbal glands, salivary glands, Harderian
glands, cranium (five sections, with oral and
nasal cavities and external and internal ear
ducts), tongue, thyroid, parathyroid, pharynx,
larynx, thymus and mediastinal lymph nodes,
trachea, lung and mainstem bronchi, heart,
diaphragm, liver, spleen, pancreas, kidneys,
adrenal glands, esophagus, stomach (fore and
glandular), intestine (four levels), urinary blad-
der, prostate (male only), vagina (female only),
gonads, interscapular brown fat pad, sub-
cutaneous and mesenteric lymph nodes, and
other organs or tissues with pathologic lesions.
All organs and tissues were preserved in 70%
ethyl alcohol except for bones, which were
fixed in 10% formalin and then decalcified
with 10% formaldehyde and 20% formic acid
in water solution. The normal specimens were
trimmed following CMCRC/ERF laboratory
standard operating procedures. The pathologic
tissue was trimmed to allow for the largest sur-
face, including normal adjacent tissue.
Trimmed specimens were processed in paraf-
ﬁn, and 3- to 5-µm sections of every specimen
were obtained. 
Sections were routinely stained with
hematoxylin and eosin. All slides were exam-
ined microscopically by the same group of
pathologists following the same criteria of
histopathologic evaluation and classiﬁcation. A
senior pathologist reviewed all tumors and all
other lesions of oncologic interest.
We performed statistical evaluations of
the incidence and dose–response relationship
of neoplastic lesions using the Cox regression
model (Cox 1972). p-Values are reported in
the tables.
Results
The experiment proceeded smoothly without
unexpected occurrences. We observed no rele-
vant differences in feed consumption between
treated and untreated groups, in either males
or females (Figure 1A,1B); no differences
were observed in water consumption between
groups or between sexes. No difference in
mean body weight was observed in the
treated groups compared with the controls
(Figure 1C). We observed a slight decrease,
seemingly dose related, in survival in the treated
groups compared with the control group in
both males and females (Figure 1D,1E).
Oncologic results are reported in Tables 1
and 2 for males and females, respectively.
Multiple tumors of different type and site, of
different type in the same site, of the same type
in bilateral organs, of the same type in the skin,
in subcutaneous tissue, in mammary glands, or
at distant sites of diffuse tissue (i.e., bones and
skeletal muscle) were plotted as single/indepen-
dent tumors. Multiple tumors of the same type
in the same tissue and organ, apart those listed
above, were plotted only once.
Total malignant tumors. The incidence of
malignant tumor–bearing animals occurred
with a significant, dose-related increase in
males (p ≤ 0.01). The incidence of malignant
tumors was significantly increased in males
treated with 2,000 ppm APM (p ≤ 0.01)
compared with controls (Table 1). Albeit not
significant, a numeric increase of the inci-
dence of animals bearing malignant tumors
was also observed among females exposed to
2,000 ppm APM compared with controls
(Table 2). Tumor types that contributed most
to this increased incidence are presented
below.
Lymphomas/leukemias. The occurrence of
lymphomas/leukemias in males and females is
reported in Tables 1 and 2. The data show that
APM causes a significant, dose-related
increased incidence in females (p ≤ 0.01).
When compared with the untreated control
group, the increased incidence of lymphomas/
leukemias in treated males and females was sig-
nificant at 2,000 ppm APM (p ≤ 0.05 and
p ≤ 0.01, respectively). In males, the most fre-
quent histotypes observed were lympho-
immunoblastic lymphomas that mainly
involved lung and mediastinal/peripheral
nodes. In females, the most frequent histotypes
Carcinogenicity of aspartame
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Table 1. Incidence of malignant tumors in male Sprague-Dawley rats exposed to APM from fetal day 12 throughout the life span.
Malignant tumorsa Total animals bearing Total animals bearing
APM dose, ppm No. of animals Tumor-bearing animalsb Total tumors lymphomas/leukemiasc mammary carcinomas
(mg/kg bw) at start No. Percent No. No./100 animals No. Percent No. Percent
2,000 (100) 70 28  40.0** 31 44.3 12  17.1* 2  2.9
400 (20) 70 18  25.7 19 27.1 11  15.7 0  —
0 (0) 95 23  24.2** 26 27.4 9  9.5 0  —
aTumor rates are based on the number of animals examined (necropsied). bp-Value associated with the dose–response test is near the control incidence. cIn male historical controls (2,265
rats), the overall incidence of lymphomas/leukemias is 20.6% (range, 8.0–30.9%). *Signiﬁcant (p ≤ 0.05) using Cox regression model. **Signiﬁcant (p ≤ 0.01) using Cox regression model.
Table 2. Incidence of malignant tumors in female Sprague-Dawley rats exposed to APM from fetal day 12 throughout the life span.
Malignant tumorsa Total animals bearing Total animals bearing
APM dose, ppm No. of animals Tumor-bearing animals Total tumors lymphomas/leukemiasb,c mammary carcinomasc
(mg/kg bw) at start No. Percent No. No./100 animals No. Percent No. Percent
2,000 (100) 70 37 52.9 60 85.7 22 31.4** 11 (15)d 15.7*
400 (20) 70 31 44.3 44 62.9 12 17.1 5 (6) 7.1
0 (0) 95 42 44.2 48 50.5 12 12.6** 5 (6) 5.3*
aTumor rates are based on the number of animals examined (necropsied). bIn female historical controls (2,274 rats), the overall incidence of lymphomas/leukemias is 13.3% (range,
4.0–25.0%), and of mammary cancers is 9.2% (range, 4.0–14.2%). cp-Values associated with the dose–response test are near the control incidence. dNumber of animals (number of
tumors); an animal can bear multiple tumors. *Signiﬁcant (p ≤ 0.05) using Cox regression model. **Signiﬁcant (p ≤ 0.01) using Cox regression model.Soffritti et al.
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were lymphocitic lymphomas and lymphoim-
munoblastic lymphomas that mainly involved
the thymus, lung, spleen, and peripheral nodes.
The differential diagnoses were based on the
morphologic criteria regularly used in our labo-
ratories, according to the guidelines of the
International Classiﬁcation of Rodent Tumors
(IARC 1993). Lymphomas/leukemias (this
term includes all types of hemolymphosarco-
mas and leukemias) are neoplasias arising from
hemolymphoreticular tissues. Their aggrega-
tion is regularly used in experimental carcino-
genesis because both solid and circulating
phases are present in many lymphoid neo-
plasms, and distinction between them is artiﬁ-
cial (Harris et al. 2001).
Mammary carcinomas. The incidence of
mammary gland carcinomas in males and
females is reported in Tables 1 and 2. A dose-
related increase in the incidence of carcino-
mas was observed in females (p ≤ 0.05). The
incidence of lesions in females exposed to
2,000 ppm APM was significantly higher
(p ≤ 0.05) compared with the controls. Two
carcinomas were also observed among males
treated with 2,000 ppm APM.
Historical controls. In our laboratory over
the last 20 years, the overall incidence of
lymphomas/leukemias was 20.6% (range,
8.0–30.9%) among 2,265 male rats and
13.3% (range, 4.0–25.0%) among 2,274
female rats. The overall incidence of mam-
mary cancers in the same group of female rats
was 9.2% (range, 4.0–14.2%).
Discussion
In our ﬁrst mega-experiment (Belpoggi et al.
2006; Soffritti et al. 2005, 2006), we demon-
strated for the ﬁrst time that APM is a multi-
potential carcinogenic agent inducing, among
other cancers, a dose-related, significant
increase in lymphomas/leukemias in females.
In the present study, in which we adminis-
tered APM (2,000 and 400 ppm; equivalent
to consumption of 100 and 20 mg/kg bw,
respectively) to Sprague-Dawley rats in feed
beginning during fetal life, we again con-
ﬁrmed that APM induces carcinogenic effects;
we found a) a signiﬁcant dose-related increase
of malignant tumor–bearing animals in males
(p < 0.01), in particular in the group treated
with 2,000 ppm APM (p < 0.01); b) a signiﬁ-
cant increase in the incidence of lymphomas/
leukemias in males in the 2,000-ppm group
(p < 0.05) and a significant dose-related
increase in the incidence of lymphomas/
leukemias in females (p < 0.01), in particular
in the 2,000-ppm group (p < 0.01); c) a signif-
icant dose-related increase in the incidence of
mammary cancer in females (p < 0.05), partic-
ularly in the 2,000-ppm group (p < 0.05). 
When comparing life-span exposure
beginning during prenatal and postnatal life,
we have shown that prenatal exposure to
APM clearly increases the incidence of lym-
phomas/leukemias in females (Table 3).
Moreover, when comparing the cumulative
prevalence by age of death of animals with
hemolymphoreticular neoplasias, it is clear
that prenatal exposure to APM also acceler-
ates the insurgence of these lesions in females
(Figure 2).
With regard to males, the incidence of lym-
phomas/leukemias in the concurrent control
(9.5%) falls within the lower range of our his-
torical controls (8.0–30.9%), and the incidence
of lymphomas/leukemias in the group treated
at the highest dose (17.1%) is close to the over-
all historical incidence (20.9%). Because the
incidence of lymphomas/leukemias observed in
males treated with 2,000 ppm APM is close to
double the concurrent control, we consider
these effects to be related to APM exposure
(Haseman 1992, 1995; Haseman et al. 1984).
The results of our second experiment (the
present study) further disprove the alternative
hypothesis suggested by the EFSA (2006)
regarding the cause of lymphomas/leukemias
in our colony, in which they considered the
incidence of lymphomas/leukemias observed
in our first experiment to be “unrelated to
APM given the high background incidence of
chronic inflammatory changes in the lung.”
First, as previously reported (Soffritti 2006),
experimental animals that are allowed to die
spontaneously are subject to infectious
pathologies that are part of the natural dying
process in both rodents and humans. Second,
among the animals bearing lymphomas/
leukemias, we observed the diffusion of neo-
plastic tissue not only in the lung but also
concurrently in various organs (liver, spleen,
mediastinal and other lymph nodes). Finally,
it should be noted that out of 49 agents
reported to be carcinogenic in rats by the
CMCRC/ERF, only 8 of these agents
induced hemolymphoreticular malignancies.
Of these, 3 were demonstrated in both males
and females—formaldehyde (Soffritti et al.
2002b), mancozeb (Belpoggi et al. 2002a),
and di-isopropyl-ether (Belpoggi et al.
2002b)—and 5 only in females—toluene
(Soffritti et al. 2004), methyl alcohol (Soffritti
et al. 2002a), methyl tert-butyl ether
(Belpoggi et al. 1995), tert-amyl-methyl-ether
(Belpoggi et al. 2002b), and APM (Belpoggi
et al. 2006; Soffritti et al. 2005, 2006). 
The two aforementioned epidemiologic
studies (Gallus et al. 2006; Lim et al. 2006)
published after our first mega-experiment
(Belpoggi et al. 2006; Soffritti et al. 2005,
2006) merit general comment. Both studies
consider the eating habits of a large population
of males and females 50–70 years of age in the
1990s. Given the time frame of these surveys
and the commercialization of aspartame in the
1980s, the subjects’ potential use of the sweet-
ener could not have exceeded 10–15 years. It
is difficult to believe that this limited adult
period of exposure to APM could conﬁrm or
exclude a potential carcinogenic risk. The
design of these studies underlines the impor-
tance of conducting an epidemiologic study in
which exposure to APM is monitored begin-
ning in fetal life, particularly given the use of
products containing APM by children and
women of child-bearing age.
Conclusions
The results of this study, our second long-
term carcinogenicity bioassay on APM, not
only confirm but also reinforce our first
experimental demonstration (Belpoggi et al.
2006; Soffritti et al. 2005, 2006) of APM’s
Table 3. Comparison of the incidence of lymphomas/leukemias in female Sprague-Dawley rats beginning
APM exposure from postnatal or prenatal life.
Percent of animals bearing lymphomas/leukemias
APM dose, ppm Postnatal exposurea  Prenatal exposure
(mg/kg bw) (No. of animals at start) (No. of animals at start)
2,000 (100) 18.7 (150) 31.4 (70)
400 (20) 20.0 (150) 17.1 (70)
0 (0) 8.7 (150) 12.6 (95)
aData from Soffritti et al. (2006).
Figure 2. Cumulative prevalence of death by age in female rats bearing hemolymphoreticular neoplasias.
(A) Postnatal APM exposure. (B) Prenatal APM exposure. Arrows indicate the start of the experiment.
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2,000 ppmmultipotental carcinogenicity at a dose level
close to the human ADI. Furthermore, the
study demonstrates that when life-span expo-
sure to APM begins during fetal life, its car-
cinogenic effects are increased.
On the basis of the present findings, we
believe that a review of the current regulations
governing the use of aspartame cannot be
delayed. This review is particularly urgent
with regard to aspartame-containing bever-
ages, which are heavily consumed by children. 
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CORRECTION
In the original manuscript published online,
Michelina Lauriola’s name was spelled
incorrectly. It has been corrected here.